Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

Summary

This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination series in children below 18 years of age.

Timeline

Start

2022-10-05

Primary completion

2022-12-15

Completion

2022-12-15

Drugs

Indications